BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 25552670)

  • 1. Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients.
    Cimitan M; Evangelista L; Hodolič M; Mariani G; Baseric T; Bodanza V; Saladini G; Volterrani D; Cervino AR; Gregianin M; Puccini G; Guidoccio F; Fettich J; Borsatti E
    J Nucl Med; 2015 Feb; 56(2):209-15. PubMed ID: 25552670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ability of 18F-choline PET/CT to identify local recurrence of prostate cancer.
    Evangelista L; Cimitan M; Hodolič M; Baseric T; Fettich J; Borsatti E
    Abdom Imaging; 2015 Oct; 40(8):3230-7. PubMed ID: 26428685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
    Castellucci P; Ceci F; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Pettinato C; Celli M; Lodi F; Fanti S
    J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
    Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
    J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.
    Graziani T; Ceci F; Castellucci P; Polverari G; Lima GM; Lodi F; Morganti AG; Ardizzoni A; Schiavina R; Fanti S
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1971-9. PubMed ID: 27277279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic performance of
    Samper Ots P; Luis Cardo A; Vallejo Ocaña C; Cabeza Rodríguez MA; Glaria Enríquez LA; Couselo Paniagua ML; Olivera Vegas J
    Clin Transl Oncol; 2019 Jun; 21(6):766-773. PubMed ID: 30448957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
    Castellucci P; Fuccio C; Rubello D; Schiavina R; Santi I; Nanni C; Allegri V; Montini GC; Ambrosini V; Boschi S; Martorana G; Marzola MC; Fanti S
    Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution.
    Marzola MC; Chondrogiannis S; Ferretti A; Grassetto G; Rampin L; Massaro A; Castellucci P; Picchio M; Al-Nahhas A; Colletti PM; Marcolongo A; Rubello D
    Clin Nucl Med; 2013 Jan; 38(1):e26-32. PubMed ID: 23242060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
    Evangelista L; Cuppari L; Guttilla A; Gardi M; Agostini A; Ruggera L; Basso U; Saladini G
    Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significant increase in detection of prostate cancer recurrence following radical prostatectomy with an early imaging acquisition protocol with ¹⁸F-fluorocholine positron emission tomography/computed tomography.
    Simone G; Di Pierro GB; Papalia R; Sciuto R; Rea S; Ferriero M; Guaglianone S; Maini CL; Gallucci M
    World J Urol; 2015 Oct; 33(10):1511-8. PubMed ID: 25577130
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Michaud L; Touijer KA; Mauguen A; Zelefsky MJ; Morris MJ; Lyashschenko SK; Durack JC; Humm JL; Weber WA; Schöder H
    J Nucl Med; 2020 Jun; 61(6):827-833. PubMed ID: 31862801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G; Picchio M; Parra RG; Briganti A; Gianolli L; Montorsi F; Messa C
    Clin Nucl Med; 2012 Apr; 37(4):325-31. PubMed ID: 22391699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of extraprostatic disease in the staging of prostate cancer by F-18 choline PET/CT: can PSA and PSA density help in patient selection?
    Calabria F; Chiaravalloti A; Tavolozza M; Ragano-Caracciolo C; Schillaci O
    Nucl Med Commun; 2013 Aug; 34(8):733-40. PubMed ID: 23680652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [(11) C]acetate PET as a prognostic marker.
    Leisser A; Pruscha K; Ubl P; Wadsak W; Mayerhöfer M; Mitterhauser M; Hacker M; Kramer G; Shariat S; Karanikas G; Hartenbach M; Haug AR
    Prostate; 2015 Nov; 75(15):1760-7. PubMed ID: 26282590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison Between
    Cantiello F; Crocerossa F; Russo GI; Gangemi V; Ferro M; Vartolomei MD; Lucarelli G; Mirabelli M; Scafuro C; Ucciero G; De Cobelli O; Morgia G; Damiano R; Cascini GL
    Clin Genitourin Cancer; 2018 Oct; 16(5):385-391. PubMed ID: 29937067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of
    Jiménez Londoño GA; García Vicente AM; Amo-Salas M; Fúnez Mayorga F; López Guerrero MA; Talavera Rubio MP; Gutierrez Martin P; González García B; de la Torre Pérez JA; Soriano Castrejón ÁM
    Rev Esp Med Nucl Imagen Mol; 2017; 36(4):241-246. PubMed ID: 28330596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 10-Year Clinical Experience With 18F-Choline PET/CT: An Italian Multicenter Retrospective Assessment of 3343 Patients.
    Zattoni F; Ravelli I; Rensi M; Capobianco D; Borsatti E; Baresic T; Chiaravalloti A; Schillaci O; Alongi P; Bartolotta TV; Rambaldi I; Bartolomei M; Farsad M; Tredici M; Donner D; Chierichetti F; Trifirò G; Brugola E; Burei M; Dal Moro F; Cecchin D; Evangelista L
    Clin Nucl Med; 2020 Aug; 45(8):594-603. PubMed ID: 32558711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation Treatment of Lymph Node Recurrence from Prostate Cancer: Is 11C-Choline PET/CT Predictive of Survival Outcomes?
    Incerti E; Fodor A; Mapelli P; Fiorino C; Alongi P; Kirienko M; Giovacchini G; Busnardo E; Gianolli L; Di Muzio N; Picchio M
    J Nucl Med; 2015 Dec; 56(12):1836-42. PubMed ID: 26405166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.